ANRS CO22 HEPATHER
Therapeutic options for hepatitis B and C: a French cohort
Keys elements
- Launched in 2012
- For a period of 10 years
- 21,000 patients with chronic-stage or cured hepatitis B (6,000) or C (15,000)
Objectives of the study
The cohort aims to improve knowledge about viral hepatitis.
Initiated in 2012, the ANRS CO22 HEPATHER cohort makes it possible to study the timecourse of liver disease of patients suffering from hepatitis C or B, in the chronic phase of the disease or cured, whether they have received treatment or not. The objective is to improve knowledge and improve patient care. These patients will be followed for approximately ten years.
It includes, to date, 20,918 patients with hepatitis B or C. More than 10,000 of them have started a new direct-acting antiviral treatment for hepatitis C under Temporary Authorizations for Use (ATU) or Marketing Authorizations (AMM).
Management and governance
The ANRS CO22 HEPATHER cohort is promoted by the ANRS-Emerging Infectious Diseases, and falls under scientific officer Pr. Fabrice Carrat, UMR-S 1136 (IPLESP), and coordinating investigators Pr. Stanislas Pol and Dr. Helene Fontaine, APHP, Paris. It brings together hepatologists from the French Association for the Study of the Liver (AFEF).
Informations détaillées
- HEPATHER web site (FR)
- Submit a research project ici (FR)
- Catalog of clinical studies based on the cohort here (FR)
- Portail Épidémiologie France (EN/FR)
No news has been published for this cohort, you can consult all the news in the spotlight section
1. Late presentation for HCV care: time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). Santos M, Protopescu C, Delarocque-Astagneau E, Bourlière M, Petrov-Sanchez V, Di Beo V, Larrey D, Baudoin M, Dorival C, Bureau M, Fontaine H, Carrat F, Marcellin F, Pol S, Carrieri P, ANRS CO22 HEPATHER study group. Liver International 2021 PMID: 34520614 DOI: 10.1111/liv.15056
2. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors’ reply.
Pol S, Lusivika Nzinga C, Carrat F. Aliment Pharmacol Ther. 2021 May;53(9):1050.doi: 10.1111/apt.16340.
3. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.
Poynard T, Lacombe JM, Deckmyn O, Peta V, Akhavan S, De Ledinghen V, Zoulim F, Samuel D, Mathurin P, Ratziu V, Thabut D, Housset C, Fontaine H, Pol S, Carrat F. JHEP Rep. 2021 Apr 24;3(4):100298.doi: 10.1016/j.jhepr.2021.100298. eCollection 2021 Aug.
- More publications here.